Company Filing History:
Years Active: 1992-1993
Title: Debra Lynn: Innovator in Recombinant Protein Research
Introduction
Debra Lynn is a prominent inventor based in Arlington, MA (US). She has made significant contributions to the field of biotechnology, particularly in the development of recombinant proteins for medical applications. With a total of 2 patents, her work has the potential to impact the diagnosis and treatment of serious diseases.
Latest Patents
Debra Lynn's latest patents focus on recombinant HTLV-III proteins and their uses. These novel recombinant fusion proteins, denoted as R10, RB1, 590, and others, are designed to aid in the diagnosis, prophylaxis, or therapy of AIDS. Specifically, protein R10 is a 95 kD fusion protein, protein PB1 is a 26 kD fusion protein, and protein 590 is an 86 kD fusion protein. Additionally, the patent includes protein KH1, which is a 70 kD fusion protein. These proteins are considered especially useful for preparing vaccines against the HTLV-III virus.
Career Highlights
Debra Lynn is associated with Repligen Corporation, where she continues to advance her research in recombinant proteins. Her innovative work has garnered attention in the scientific community, contributing to the understanding and potential treatment of viral infections.
Collaborations
Debra has collaborated with notable colleagues, including Scott D Putney and Kashayar Javaherian. These partnerships have further enriched her research and development efforts in the field of biotechnology.
Conclusion
Debra Lynn's contributions to recombinant protein research highlight her role as an influential inventor in the biotechnology sector. Her innovative patents pave the way for advancements in medical treatments and vaccines.